Drug
Abiraterone clinical trials
Also written CB 7598 and JNJ-212082.
Includes 143 studies of Abiraterone Acetate.
- studies test it
- 195
- open now
- 25
- in phase 3
- 19
- first study started
- 2005
Keep track of what changes. Save the abiraterone studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
195 studies that test it; most in 2012 (20)
| Year | Studies |
|---|---|
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 4 |
| 2008 | 2 |
| 2009 | 7 |
| 2010 | 4 |
| 2011 | 8 |
| 2012 | 20 |
| 2013 | 14 |
| 2014 | 15 |
| 2015 | 6 |
| 2016 | 11 |
| 2017 | 17 |
| 2018 | 7 |
| 2019 | 10 |
| 2020 | 17 |
| 2021 | 15 |
| 2022 | 9 |
| 2023 | 7 |
| 2024 | 7 |
| 2025 | 8 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 63
- Phase 2
- 123
- Phase 3
- 19
- Phase 4
- 4
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 77 · Other 118
Janssen Research & Development, LLC (27) · Cougar Biotechnology, Inc. (10) · Dana-Farber Cancer Institute (7) · M.D. Anderson Cancer Center (5) · University of Washington (5) · Memorial Sloan Kettering Cancer Center (4) · Jiangsu HengRui Medicine Co., Ltd. (4) · Novartis Pharmaceuticals (3)
Often tested with
Tested in the same studies.
Prednisone (51) · Enzalutamide (27) · Apalutamide (24) · Leuprolide (8) · Docetaxel (8) · Niraparib (7) · Cabazitaxel (7) · Prednisolone (6)
Studies
Open first, then newest update. How each study uses abiraterone is read from its arms, and is right about nine times in ten.
Testing it · 195
- Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate CancerRecruitingPhase 2University of NebraskaNCT07237269Written as Abiraterone
- A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPCRecruitingPhase 1/2Novartis PharmaceuticalsNCT07226986Written as Abiraterone
- A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN LossRecruitingPhase 2VA Office of Research and DevelopmentNCT05593497Written as abiraterone acetate
- Targeted Treatment for Metastatic Prostate Cancer, The PREDICT TrialRecruitingPhase 2Alliance for Clinical Trials in OncologyNCT06632977Written as Abiraterone Acetate
- TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)RecruitingPhase 1/2Novartis PharmaceuticalsNCT07190300Written as Abiraterone
- Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE TrialRecruitingPhase 2Mayo ClinicNCT07650240Written as Abiraterone Acetate
- Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyEnrolling by invitationPhase 3ExelixisNCT07620574Written as Abiraterone
- Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate CancerRecruitingPhase 2University of British ColumbiaNCT04812366Written as Abiraterone Acetate 250mg
- Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)RecruitingPhase 2University Health Network, TorontoNCT05404139Written as Abiraterone
- Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Prostate Cancer Patients.RecruitingPhase 2Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología RadioterápicNCT07717268Written as Zytiga® (Abiraterone Acetate)
- Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC StudyRecruitingPhase 2University of WashingtonNCT04175431Written as Abiraterone Acetate
- SNV1521 in Participants With Advanced Solid TumorsRecruitingPhase 1Synnovation Therapeutics, Inc.NCT06220864Written as Abiraterone
- Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.RecruitingPhase 2Sun Pharmaceutical Industries LimitedNCT05422911Written as Abiraterone acetate
- Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate CancerRecruitingPhase 2University of California, DavisNCT06173362Written as Abiraterone
- Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate CancerRecruitingPhase 2City of Hope Medical CenterNCT04734730Written as Abiraterone Acetate
- Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2)RecruitingPhase 2SMED Clinical ResearchNCT07299292Written as Abiraterone 250 mg with food + prednisone
- Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate CancerRecruitingPhase 2Martha MimsNCT03833921Written as Abiraterone Acetate
- Efficacy and Safety of Disitamab Vedotin Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer:a Phase II StudyRecruitingPhase 2The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT07093866Written as Abiraterone + prednisone
- Determining the Effect of Abiraterone on the Metabolism of Oxycodone in Men With Prostate Cancer (the ENABLE Study)RecruitingPhase 4Deventer ZiekenhuisNCT07001709Written as Abiraterone Acetate Tablets 500 mg
- ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate CancerRecruitingPhase 3Karolinska InstitutetNCT03903835Written as Abiraterone Oral Tablet
See all 195 studies that test abiraterone →
Given in every arm · 78 — abiraterone is usual care beside what is tested
- A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate CancerRecruitingPhase 1Novartis PharmaceuticalsNCT07570979Written as Abiraterone
- A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid TumorsRecruitingPhase 1/2DualityBio Inc.NCT05914116Written as Abiraterone
- A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerRecruitingPhase 3AmgenNCT07213674Written as Abiraterone acetate
- Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)RecruitingPhase 3AstraZenecaNCT07711002Written as Abiraterone
- A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA MutationRecruitingPhase 3AstraZenecaNCT06952803Written as Abiraterone + Prednisolone/Prednisone
- A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06863272Written as Abiraterone
- Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate CancerRecruitingPhase 3SWOG Cancer Research NetworkNCT03678025Written as Abiraterone
- A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate CancerRecruitingPhase 1Janssen Research & Development, LLCNCT05818683Written as Abiraterone acetate plus prednisone (AAP)
- Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate CancerRecruitingPhase 1AmgenNCT04221542Written as Abiraterone
- A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate CancerNot yet recruitingPhase 2/3Sichuan Baili Pharmaceutical Co., Ltd.NCT07641855Written as Abiraterone
- The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)RecruitingPhase 3Telix Pharmaceuticals (Innovations) Pty LimitedNCT06520345Written as Abiraterone
- Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA ResponseRecruitingPhase 3Canadian Cancer Trials GroupNCT06592924Written as Abiraterone
- Study of ORIC-944 in Patients With Metastatic Prostate CancerRecruitingPhase 1ORIC PharmaceuticalsNCT05413421Written as Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets
- Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate CancerRecruitingPhase 1AmgenNCT07140900Written as Abiraterone
- A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate CancerRecruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT06457919Written as abiraterone acetate with prednisone
- Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate CancerRecruitingPhase 2M.D. Anderson Cancer CenterNCT04947254Written as Abiraterone Acetate
- A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate CancerRecruitingPhase 1/2Qilu Pharmaceutical Co., Ltd.NCT07198633Written as abiraterone acetate
- A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate CancerRecruitingPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT07230106Written as Abiraterone Tablet
- REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac TrialRecruitingPhase 3Emory UniversityNCT06650579Written as Abiraterone Acetate
- Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate CancerRecruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06616597Written as Abiraterone acetate
Showing 20 of 78.
As the comparator · 23 — what is tested is compared with abiraterone
- A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06136650Written as Abiraterone acetate
- AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)RecruitingPhase 3AstraZenecaNCT07611110Written as Abiraterone
- A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate CancerRecruitingPhase 2Hoffmann-La RocheNCT07287150Written as Abiraterone
- Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06136624Written as Abiraterone acetate
- A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]RecruitingPhase 3GlaxoSmithKlineNCT07802704Written as Abiraterone
- Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate CancerNot yet recruitingPhase 2/3ECOG-ACRIN Cancer Research GroupNCT07852195Written as Abiraterone Acetate
- A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate CancerRecruitingPhase 2Astellas Pharma Global Development, Inc.NCT07005154Written as abiraterone acetate
- Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)RecruitingPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT05942001Written as Abiraterone acetate tablets
- Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE TrialRecruitingPhase 2Mayo ClinicNCT06378866Written as Abiraterone
- A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate CancerActive, not recruitingPhase 3CelgeneNCT06764485Written as Abiraterone
- Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing SurgeryActive, not recruitingPhase 2Rutgers, The State University of New JerseyNCT02949284Written as Abiraterone Acetate
- Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)Active, not recruitingPhase 3AmgenNCT06691984Written as Abiraterone
- A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate CancerActive, not recruitingPhase 2R-Pharm International, LLCNCT07553988Written as Abiraterone
- Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 MutationsActive, not recruitingPhase 4AstraZenecaNCT05457257Written as abiraterone acetate
- A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid TumorsTerminatedPhase 2MacroGenicsNCT05551117Written as Abiraterone
- Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal TreatmentActive, not recruitingPhase 3POINT Biopharma, a wholly owned subsidiary of Eli Lilly and CompanyNCT04647526Written as Abiraterone
- Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPCActive, not recruitingPhase 3ExelixisNCT04446117Written as Abiraterone Acetate
- Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)CompletedPhase 3Merck Sharp & Dohme LLCNCT03834519Written as Abiraterone acetate
- Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting AgentTerminatedPhase 3Veru Inc.NCT04844749Written as Enzalutamide, Abiraterone
- TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate CancerCompletedPhase 3Tavanta TherapeuticsNCT04887506Written as Zytiga
Showing 20 of 23.
Codes
What other systems call abiraterone · ClinicalTrials.gg INT003801
- MeSH (NLM) C089740abirateroneConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) G819A456D0ABIRATERONEConfirmed FDA, NLM, Wikidata
- RxNorm 1100072Confirmed FDA, Wikidata
- Wikidata Q321431abirateroneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C77333AbirateroneOne source FDA
- DrugBank DB05812One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C089740 | abiraterone | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | G819A456D0 | ABIRATERONE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1100072 | — | Confirmed FDA, Wikidata |
| Wikidata | Q321431 | abiraterone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C77333 | Abiraterone | One source FDA |
| DrugBank | DB05812 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.